Clinical Trial Update: Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain [Phase 2]

View source ↗

Summary

Phase 2 trial of IDN5243 for low back pain has been withdrawn; the document notes tolerability, safety and activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low Back Pain

Drugs mentioned

• IDN5243 (IDN5243)

Snippet

Sponsor: Indena S.p.A | Conditions: Low Back Pain | Phase 2 | Status: WITHDRAWN